inflammatory%20bowel%20disease
INFLAMMATORY BOWEL DISEASE
Inflammatory bowel disease consists of ulcerative colitis and Crohn's disease.
Ulcerative colitis is a diffuse mucosal inflammation limited to the colon while Crohn's disease is a patchy, transmural inflammation that occurs in any part of the gastrointestinal tract.
The ileum and colon are the most frequently affected sites.

Inflammatory Bowel Disease Drug Information

Drug Information

Indication: Prophylaxis of transplant rejection in adult kidney or liver allograft receipients. Kidney or liver allograft ...

Indication: Primary immunosuppression in liver & kidney allograft recipients & liver & kidney allograft reject...

Indication: Symptomatic treatment of allergic dermatoses & other forms of contact dermatitis, insect bites; atopic, ec...

Indication: Rheumatic fever, RA, allergic diseases, nephritic syndrome, bronchial asthma & other corticosteroid-indica...

Indication: Adjuvant of maintenance therapy & short-term administration in psoriatic arthritis, ankylosing spondylitis...

Indication: Non-infected acute dermatitis or eczema, including infantile eczema, atopic eczema, contact & allergic der...

Indication: Urogenital trichomoniasis in both genders. All forms of amoebiasis (intestinal & extraintestinal disease &...

Indication: Eczema, infantile eczema, atopic dermatitis, dermatitis herpetiformis, contact dermatitis, neurodermatitis, ps...

Indication: Relief of inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses.

Indication: Immunosuppressant antimetabolite, organ transplants, autoimmune chronic active hepatitis, severe RA, SLE, chro...

1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.